Next Article in Journal
Application of Biodegradable and Biocompatible Nanocomposites in Electronics: Current Status and Future Directions
Previous Article in Journal
Phenol Abatement by Titanium Dioxide Photocatalysts: Effect of The Graphene Oxide Loading
Article Menu

Export Article

Open AccessArticle

Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors

1
Departamento de Ingeniería Química y Textil, Facultad de Ciencias Químicas, Universidad de Salamanca, 37008 Salamanca, Spain
2
Instituto de Biología Molecular y Celular del Cáncer (IBMCC), CSIC, CIBERONC-IBSAL, 37007 Salamanca, Spain
*
Author to whom correspondence should be addressed.
Nanomaterials 2019, 9(7), 948; https://doi.org/10.3390/nano9070948
Received: 10 June 2019 / Revised: 26 June 2019 / Accepted: 28 June 2019 / Published: 29 June 2019
  |  
PDF [1830 KB, uploaded 1 July 2019]
  |     |  

Abstract

Paclitaxel is one of the most widely used chemotherapeutic agents thanks to its effectiveness and broad spectrum of antitumor activity. However, it has a very poor aqueous solubility and a limited specificity. To solve these handicaps, a novel paclitaxel-trastuzumab targeted transport nanosystem has been developed and characterized in this work to specifically treat cancer cells that overexpress the human epidermal growth factor receptor-2 (HER2). Methods: Alginate and piperazine nanoparticles were synthetized and conjugated with paclitaxel:β-cyclodextrins complexes and trastuzumab. Conjugated nanoparticles (300 nm) were characterized and their internalization in HER2-overexpressing tumor cells was analyzed by immunofluorescence. Its specific antitumor activity was studied in vitro using human cell lines with different levels of HER2-expression. Results: In comparison with free paclitaxel:β-cyclodextrins complexes, the developed conjugated nanovehicle presented specificity for the treatment of HER2-overpressing cells, in which it was internalized by endocytosis. Conclusions: It seems that potentially avoiding the conventional adverse effects of paclitaxel treatment could be possible with the use of the proposed mixed nanovehicle, which improves its bioavailability and targets HER2-positive cancer cells. View Full-Text
Keywords: targeted nanoparticles; paclitaxel; trastuzumab; HER2-specificity; sodium alginate; piperazine targeted nanoparticles; paclitaxel; trastuzumab; HER2-specificity; sodium alginate; piperazine
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Nieto, C.; Centa, A.; Rodríguez-Rodríguez, J.A.; Pandiella, A.; Martín del Valle, E.M. Paclitaxel-Trastuzumab Mixed Nanovehicle to Target HER2-Overexpressing Tumors. Nanomaterials 2019, 9, 948.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top